article Open AccessTop 1% cited
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
Journal of Bone and Mineral Research · 2008 · Vol. 23(6) · pp. 826–836
Ana O. Hoff✉(The University of Texas MD Anderson Cancer Center)Béla B. Toth(The University of Texas MD Anderson Cancer Center)Kadri Altundağ(The University of Texas MD Anderson Cancer Center)Marcella M. Johnson(The University of Texas MD Anderson Cancer Center)Carla L. Warneke(The University of Texas MD Anderson Cancer Center)Mimi I. Hu(The University of Texas MD Anderson Cancer Center)Ajay K. Nooka(The University of Texas MD Anderson Cancer Center)Gilbert Sayegh(The University of Texas MD Anderson Cancer Center)Valentina Guarneri(The University of Texas MD Anderson Cancer Center)Kimberly Desrouleaux(The University of Texas MD Anderson Cancer Center)Jeffrey Cui(The University of Texas MD Anderson Cancer Center)Andrea Adamus(The University of Texas MD Anderson Cancer Center)Robert F. Gagel(The University of Texas MD Anderson Cancer Center)Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)
Abstract
ONJ is an uncommon but long-lasting disorder that occurs mainly in breast cancer and multiple myeloma patients treated with intravenous bisphosphonates. High cumulative doses of bisphosphonates, poor oral health, and dental extractions may be significant risk factors for ONJ development. ONJ resolved in 23% of patients with conservative therapy.
Bone health and treatmentsBone and Joint DiseasesCancer Diagnosis and TreatmentOsteonecrosis of the jawMedicineCancerDentistryInternal medicineBisphosphonateOsteoporosis
MeSH terms
AdolescentAdultAgedAged, 80 and overBreast NeoplasmsChildChild, PreschoolDiphosphonatesFemaleHumansInfusions, IntravenousJaw NeoplasmsMaleMiddle AgedMultiple Myeloma
Funding
- National Institutes of Health
- National Cancer Institute
Citations
632
FWCI
30.39
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
Cited by
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
Journal of Oral and Maxillofacial Surgery · 2014 · 2,869 citations
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Journal of Bone and Mineral Research · 2014 · 1,324 citations
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update
Journal of Oral and Maxillofacial Surgery · 2009 · 1,323 citations
Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
Journal of Oral and Maxillofacial Surgery · 2009 · 488 citations
American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
Journal of Oral and Maxillofacial Surgery · 2022 · 989 citations
References
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Journal of Oral and Maxillofacial Surgery · 2004 · 2,052 citations
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
The Journal of Clinical Endocrinology & Metabolism · 2005 · 1,422 citations
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic
Journal of Oral and Maxillofacial Surgery · 2003 · 3,014 citations
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · 1,654 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.